Pfenex’ Forteo biosimilar PF708 secures FDA approval for osteoporosis

This article was originally published here

The regulator approved the new drug application (NDA) for PF708, which was submitted under the 505(b)(2) regulatory pathway with Eli Lilly and Company’s Forteo as the reference medicine.

The post Pfenex’ Forteo biosimilar PF708 secures FDA approval for osteoporosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply